Cansino Biologics Inc.

CanSino Biologics Inc. (CanSinoBIO, stock 6185.HK) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with now more than 450 employees, one approved vaccine for Ebola virus disease (Ad5-EBOV) and 16 vaccine candidates in the product pipeline. CanSinoBIO has been successfully listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) since March 2019. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies. In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company. CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, covering meningitis, tuberculosis, Novel coronavirus pneumonia, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Among these, Ad5-EBOV, the globally innovative Ebola virus disease vaccine, has received NDA (New Drug Application) approval in China in October 2017. Moreover, the NDA applications of two meningococcal conjugate vaccines are under NMPA review. Additionally, CanSinoBIO has seven vaccine candidates in the clinical trial stage or clinical trial application stage. There are also six pre-clinical vaccine candidates under development, including one combination vaccine candidate. CanSinoBIO currently has a Research and Development Center with a floor space of approximately 120,000 square-feet as well as a 380,000 square-feet commercial manufacturing campus, which is designed, qualified and operated according to international cGMP standards (FDA, EU, WHO and China). The GMP pilot plants located in the R&D center have passed EU QPs’ audits. The annual bulk production capacity of the current facilities can reach approximately 70 million to 80 million doses, which will be capable of supporting our commercialization plans for our near-commercial vaccine candidates. Vaccination is an essential part of effective disease control and prevention. CanSinoBIO is committed to make innovative and high quality vaccines accessible to people all over the world thus empower people to pursue healthy and better life.